-
公开(公告)号：US11930837B2
公开(公告)日：2024-03-19
申请号：US17403710
申请日：2021-08-16
申请人： NOVARTIS AG
IPC分类号： A61K38/20 , A23L7/10 , A23L7/104 , B02B1/04 , B02C4/06 , B02C4/16 , B02C9/00 , B02C23/18 , B02C23/40 , C07K16/46 , B02C15/14
CPC分类号： A23L7/197 , A23L7/104 , A61K38/2013 , B02B1/04 , B02C4/06 , B02C4/16 , B02C9/00 , B02C23/18 , B02C23/40 , C07K16/46 , A23V2002/00 , B02C15/14
摘要： The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
-
公开(公告)号：US20220346415A1
公开(公告)日：2022-11-03
申请号：US17813232
申请日：2022-07-18
申请人： NOVARTIS AG
IPC分类号： A23L7/10 , A23L7/104 , A61K38/20 , B02B1/04 , B02C4/06 , B02C4/16 , B02C9/00 , B02C23/18 , B02C23/40 , C07K16/46
摘要： The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
-
公开(公告)号：US11122825B2
公开(公告)日：2021-09-21
申请号：US16616138
申请日：2018-05-22
申请人： NOVARTIS AG
IPC分类号： A61K38/20 , A23L7/10 , A23L7/104 , B02C4/16 , B02C4/06 , B02C23/40 , B02B1/04 , B02C9/00 , B02C23/18 , C07K16/46 , B02C15/14
摘要： The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
-
公开(公告)号：US12006354B2
公开(公告)日：2024-06-11
申请号：US16616318
申请日：2018-05-22
申请人： NOVARTIS AG
IPC分类号： C07K14/55 , A61K38/20 , A61K39/395 , A61K47/68 , A61P35/00 , C07K16/08 , C07K16/10 , C07K19/00 , C12N5/071 , C12N5/0783 , A61K39/00 , A61K45/06
CPC分类号： C07K16/1027 , A61K38/2013 , A61K39/3955 , A61K47/6801 , A61P35/00 , C07K14/55 , C07K19/00 , C12N5/0636 , C12N5/0682 , A61K2039/505 , A61K45/06 , C07K2317/56 , C07K2317/565 , C07K2317/94 , C07K2319/30
摘要： The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.
-
公开(公告)号：US20200270334A1
公开(公告)日：2020-08-27
申请号：US16616318
申请日：2018-05-22
申请人： NOVARTIS AG
IPC分类号： C07K16/10 , C07K14/55 , C12N5/0783 , A61K39/395 , A61K45/06 , C12N5/071 , A61P35/00
摘要： The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
